ABSTRACT
Introduction
Experimental models of bone regeneration using critical defects with no spontaneous regeneration have been used to analyze different substances with osteoinductive properties, which are specifically able to induce the differentiation of osteoprogenitor cells into osteoblasts and induce bone formation 1, 2 . New bone formation is triggered by an inducing substance present in the bone collagen matrix known as bone morphogenetic protein (BMP) 3 .
BMPs are non-collagenous proteins responsible for chemotaxis, proliferation of mesenchymal cells, osteoblast differentiation and bone formation 4, 5 . Drugs called statins have been used for over 30 years to treat hyperlipidemia and arteriosclerosis. These drugs may stimulate the expression of BMP2 and prevent the prenylation of some GTPase proteins 6, 7 .
Statins may also stimulate the expression of vascular endothelial growth factor (VEGF), which stimulates the differentiation of endothelial progenitor cells (EPCs) and, thus, stimulate angiogenesis 8 . Statins also reduce bone resorption and therefore inhibit farnesylpyrophosphate (geranilgeranilpirofosfato), which is essential for cell differentiation and the function of osteoclasts 6 .
However, clinical studies and systematic reviews have shown no correlation between the use of oral statins and bone density, osteoporosis or the prevention of bone fractures 9, 10 . In vitro studies of simvastatin and its local application in experimental bone defects has demonstrated, after histological and immunohistochemical analyses, that simvastatin increases the expression of the growth factors VEGF and BMP2, which are major regulators of angiogenesis and osteogenesis 11,12. A consensus has not yet been reached on the dose of simvastatin and the manner in which it should be provided locally.
Within this context, the objective of this study was to evaluate the effect of a local application of simvastatin in the gel state on the repair of bone defects in rabbit femurs.
Methods
The experimental protocol (#1913/08) was approved by the Ethics Committee of the Sao Paulo Federal University (UNIFESP). The study was designed as a randomized, controlled trial with a blinded assessment of the outcome.
Eighteen albino rabbits (Oryctolagus cuniculus), which were male, five months old, and weighed 3000 g, underwent anesthesia with 0.1 ml of xylazine/kg and 50 mg/kg of ketamine injected intramuscularly. A linear 5 cm incision was made in the outer left thigh over the femoral epiphysis toward to the caudal region. With a digital electric micro-drill, which was under continuous saline irrigation and near the epiphysis, two standard and non-critical (4 mm diameter and 6 mm deep) bone cavities (proximal and distal) were prepared with a 10 mm distance between the two cavities. Subsequently, 1 mg of simvastatin gel (0.5 ml)
mixed with a vehicle of 1% hydroxypropyl methylcellulose (0.5 ml) was applied. To avoid dispersion of the simvastatin gel and to maintain the gel within the bone cavity, we used an absorbable, hydrolyzed and lyophilized collagen sponge (Technew-Cod.
ANVISA n°: 80015520006) as a plug. To prevent invagination of non-osteogenic cells in both bone cavities, the cavities were coated with a membrane of resorbable bovine bone collagen (GenDermBaumer-Genius Biomaterials -Cod. ANVISA n°: 10345500069).
The animals were randomly assigned to one of two groups. In the simvastatin group (SIN), the bone cavity was filled with an absorbable collagen sponge (0.02 g) soaked in 0.5 ml of simvastatin gel (SIN 1 mg / HPMC 0.5 ml) and biological membrane collagen. In the control group (CON), the bone cavity was filled with a blood clot and biological membrane collagen.
The wound was sutured with mononylon 4.0. To promote analgesia and antimicrobial therapy, the animals received ketoprofen and enrofloxacin for five consecutive days. After surgery, the animals were randomly assigned into one of three periods of observation:
seven, 21 or 42 days.
After euthanasia under anesthesia, the left femurs were fixed in 10% formalin and were decalcified in trichloroacetic acid 
Statistical analysis
To determine the differences between the two groups and between the three observation time periods, the results of the descriptive analysis were subject to a nonparametric Wilcoxon test (for paired samples), and the level for the rejection of the null hypothesis was set at 5% (p<0.05).
Results

Histological evaluation
At seven days of observation ( 
Immunohistochemistry evaluation
At seven days of observation, there was a significant presence of VEGF, which matched the greater frequency of neovascularization observed from the HE staining. At twenty-one days, the VEGF was not statistically significant, which was unlike the osteocalcin, which was significantly more prevalent at this time. At forty-two days, the two markers did not show differences between the groups (Figure 4 Our animal model created a bone defect that was regarded as a non-critical injury (4 mm diameter and 6 mm deep) and only removed the cortical layer. It was a defect that the body would be able to spontaneously repair by replacing the defect with new bone tissue without the need for some type of treatment. The purpose was to verify that the use of an osteoinductive material could shorten the time needed to repair the defect.
The femoral epiphysis has characteristics suitable for the preparation of cavities because it presents red bone marrow with a large amount of spongy bone and osteoprogenitor cells. Furthermore, the epiphysis of the femur allows for the creation of a defect with a larger diameter and depth without increasing the risk of fracture.
With a trephine having a 4.0 mm diameter, it was possible to prepare two cavities in each femoral epiphysis with a minimal risk of hip fracture, which, in fact, did not occur in any animal.
Simvastatin is characterized as a lipophilic statin that can passively penetrate the cell membrane and exert its effect at the tissue level. We applied the simvastatin in gel form through an association with a vehicle: hidroxipropilenometilcelulose The success of bone repair depends on the permanence time and on the absorption of the material at the site of the bone defect 20, 21 . The absorbable collagen sponge allowed the simvastatin gel to remain in the bone cavity, while not interfering with the drug's action 11, 18 . A physical barrier (osteo promoter) was positioned and was composed of a resorbable collagen membrane overlying the opening of the bone defect with the intent of retaining the soft tissue and, thus, allowing only the cells originating from the bone tissue to occupy the area of the lesion.
Some authors did not observe new bone formation induced by simvastatin [22] [23] [24] . Other reports indicate that simvastatin 17, [25] [26] [27] [28] influenced and stimulated new bone formation. There are few consistent studies on the anabolic effects and bioavailability of simvastatin, which is a fact that leads to such varying results among several studies 29 . 
Discussion
The development of new biomaterials has been conducted with the aim of identifying new methods of stimulating cytokines and growth factors focused on osteoinductive, osteoconductive and angiogenic actions. These biomaterials need to be easy to manipulate, be absorbable and have a physical structure capable of maintaining a space for bone formation without generating an appreciable immune response. Despite major advances in science and technology, there is not a substance that meets the majority of these requirements 13, 14 .
Bone defects have been used as experimental models for the study of bone regeneration because the repair of these defects resembles the direct repair of fractures. Other models have been reported using animals, such as rats, rabbits, cats, dogs, pigs, monkeys, and have been conducted using bone defects in the calvaria, the jaw or in long bones 15 .
The rabbit model has the advantage that it is easy to handle the animals and allows for larger bone defects compared with rats, mice or guinea pigs. The exclusive use of males avoided the possible hormonal changes present in females because this could compromise the results. There is a consensus that the cycle
The results obtained in this study for the period of seven days, which is considered to be the initial phase of bone healing, showed increased vascularity with a significantly greater amount of newly formed vessels in the simvastatin group compared with the control group (Figure 1 ). There was also a statistically significant greater antibody immunostaining for VEGF in the simvastatin group compared with the control group (Figure 4) . These results are in agreement with other studies 11, 12, 18 , and it can be inferred that, in the acute phase of bone repair, simvastatin had a beneficial effect on stimulating the production of new vessels, which might reflect an advantage for subsequent stages of bone regeneration. For the other variables, although the mean was identical and the median was greater in the simvastatin group, there was no statistically significant difference between the groups with slight immune-staining for VEGF, large amounts of osteoblasts and moderate amounts of osteoclasts. Again, a larger sample size or a more sensitive marker may help to confirm this favorable trend for the use of simvastatin in future studies.
During the forty-two day observation period, we documented an intense reactive bone formation as well as greater scores for bone tissue formation in the simvastatin group compared with the control group (Figure 3 ). More osteoblasts were observed with greater scores in the simvastatin group compared with the control group (Figure 3) . The same occurred with the osteoclasts with greater scores in the simvastatin group compared with the control group. These results are in agreement with other studies [16] [17] [18] [19] 26 . In the late period of regeneration, simvastatin was able to stimulate a greater presence of osteoblasts and subsequent bone formation.
The remaining variables showed no statistically significant difference between the groups, but we observed discrete neovascularization in the two groups and moderate fibrosis still present in the control group. Intense and greater immune-staining for osteocalcin antibody in the simvastatin group was observed compared with the control group as well as mild immune-staining for VEGF in both groups (Figure 4 ).
Given the results, the proposed model of topical application of the simvastatin proved to be efficient and effective.
The applied drug was stable and persisted in cavities that were made in the femurs of rabbits, which shows that this method of offering the drug should be studied in more detail in the future.
Moreover, the beneficial effects of simvastatin have been shown at different stages during the biological process of bone repair. At the 7 th day, simvastatin's effect was greatly expressed in stimulating vascularization, and this time point is the crucial point of the acute phase. Fibroblast proliferation and marked bone formation was observed on the 21 th day and persisted to the 42 nd day with a significant expression of osteoblasts and osteoclasts.
Conclusion
Surgical defects created in rabbit femurs were treated locally with simvastatin gel to stimulate bone repair, which promoted an ameliorative effect in the morphological and immunohistochemical markers of bone regeneration.
